Cost savings following tissue plasminogen activator (IV TPA) on a Canadian stroke unit

被引：0
|
作者：
Gubitz, G
Phillips, S
Jarrett, J
机构：
来源：
STROKE | 2000年 / 31卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
066
引用
收藏
页码：2888 / 2888
页数：1
相关论文
共 50 条
  • [21] Use of Tissue Plasminogen Activator (TPA) in the Setting of Acute Stroke in Patients with Intracranial Aneurysms
    Juersivich, Adam
    Kelly, Adam
    [J]. NEUROLOGY, 2012, 78
  • [22] Tissue plasminogen activator (tPA) in acute ischaemic stroke: time for collegiate communication and consensus
    Rogers, IR
    Jelinek, GA
    Jacobs, I
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 2005, 182 (01) : 45 - 45
  • [23] Risk of Intracranial Hemorrhage Following Intravenous tPA (Tissue-Type Plasminogen Activator) for Acute Stroke Is Low in Children
    Amlie-Lefond, Catherine
    Shaw, Dennis W. W.
    Cooper, Andrew
    Wainwright, Mark S.
    Kirton, Adam
    Felling, Ryan J.
    Abraham, Michael G.
    Mackay, Mark T.
    Dowling, Michael M.
    Torres, Marcela
    Rivkin, Michael J.
    Grabowski, Eric F.
    Lee, Sarah
    Kurz, Jonathan E.
    McMillan, Hugh J.
    Barry, Dwight
    Lee-Eng, Jacqueline
    Ichord, Rebecca N.
    [J]. STROKE, 2020, 51 (02) : 542 - 548
  • [24] Recombinant tissue plasminogen activator (rtPA) and stroke unit for acute ischaemic stroke in developing countries, are they cost-effective?
    Shahtaheri, Rahil Alsadat
    Borhani Haghighi, Afshin
    Safari, Anahid
    Cruz-Flores, Salvador
    [J]. INTERNATIONAL JOURNAL OF STROKE, 2012, 7 (07) : E9 - E9
  • [25] Functional Recovery Following a Combination of Thrombin Inhibitor Argatroban and Tissue Plasminogen Activator (tPA) in Thromboembolic Stroke in Nonhuman Primates
    Suzuki, Junko
    Itani, Yoshitaka
    Ogawa, Shinya
    Yamanaka, Kazunori
    Hayashi, Ikuo
    Takamatsu, Hiroyuki
    [J]. STROKE, 2017, 48
  • [26] The vasoactivity of tissue type plasminogen activator (tPA) and TNK-tPA
    Nassar, H
    Nassar, T
    Haj-Yehia, A
    Akkawi, S
    Bdeir, K
    Higazi, AR
    [J]. ATHEROSCLEROSIS SUPPLEMENTS, 2003, 4 (02) : 250 - 250
  • [27] SAFETY AND EFFICACY OF INTRAVENOUS RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR (IV R-TPA) IN ACUTE STROKE; A SINGLE CENTER EXPERIENCE
    Taheraghdam, A.
    Farhoudi, M.
    Haghighi, A. Borhan
    Rikhtegar, R.
    Sadeghi-Hokmabadi, E.
    Mehrvar, K.
    Mahmoodi, P.
    Mirnour, R.
    Hassasi, R.
    Tamar, S. Hasaneh
    Asadi, R.
    Mehdizadehfar, E.
    [J]. INTERNATIONAL JOURNAL OF STROKE, 2016, 11 (SUPP 3) : 181 - 181
  • [28] Elevated tissue plasminogen activator (tPA) antigen and stroke risk: The stroke prevention in young women study
    Macko, RF
    Kittner, SJ
    Feeser, BR
    Cox, DK
    Hebel, JR
    Buchholz, DW
    Earley, CJ
    Johnson, CJ
    Price, TR
    Sloan, MA
    Stern, BJ
    Wityk, RJ
    Wozniak, MA
    Sherwin, RW
    Stolley, PD
    [J]. CIRCULATION, 1996, 93 (03) : P44 - P44
  • [29] Cost-utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke - A Canadian healthcare perspective
    Sinclair, SE
    Frighetto, L
    Loewen, PS
    Sunderji, R
    Teal, P
    Fagan, SC
    Marra, CA
    [J]. PHARMACOECONOMICS, 2001, 19 (09) : 927 - 936
  • [30] Tissue plasminogen activator (tPA) in outflow facility regulation
    Arrambide, Arturo Osvaldo Barron
    Gindina, Sofya
    Hu, Yan
    Danias, John
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2020, 61 (07)
12345